Safety and patient experiences with the natalizumab biosimilar in multiple sclerosis treatment
Multiple Sclerosis and Related Disorders · 2026-05 · 109 · 107147
DOI: 10.1016/j.msard.2026.107147 ↗Kurz gefasst
Fachartikel in der Zeitschrift Multiple Sclerosis and Related Disorders, 2026-05. Verfasst von Liza M Y Gelissen und 7 weiteren Autor:innen. Beteiligte Einrichtung: MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Centers, Location De Boelelaan, Am…. Hauptthemen laut MEDLINE: Natalizumab, Biosimilar Pharmaceuticals, Immunologic Factors, Patient Satisfaction. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Centers, Location De Boelelaan, Amsterdam, the Netherlands. Electronic address: l.m.y.gelissen@amsterdam…
- MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Centers, Location De Boelelaan, Amsterdam, the Netherlands.
- Department of Clinical Pharmacology and Pharmacy, Amsterdam University Medical Centers, Location De Boelelaan, Amsterdam, the Netherlands.
- Research & Lab Services Dept, Sanquin Blood Supply, Amsterdam, the Netherlands; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherla…
Zitieren
APA
Gelissen, L. M. Y., Strijbis, E. M. M., van Oosten, B. W., de Jong, B. A., Veldkamp, A. I., Rispens, T., Killestein, J., & van Kempen, Z. L. E. (2026). Safety and patient experiences with the natalizumab biosimilar in multiple sclerosis treatment. Multiple Sclerosis and Related Disorders, 109, 107147. https://doi.org/10.1016/j.msard.2026.107147
Vancouver
Gelissen LMY, Strijbis EMM, van Oosten BW, de Jong BA, Veldkamp AI, Rispens T, et al. Safety and patient experiences with the natalizumab biosimilar in multiple sclerosis treatment. Multiple Sclerosis and Related Disorders. 2026;109:107147. doi:10.1016/j.msard.2026.107147
BibTeX
@article{Gelissen2026,
author = {Gelissen, Liza M Y and Strijbis, Eva M M and van Oosten, Bob W and de Jong, Brigit A and Veldkamp, Agnes I and Rispens, Theo and Killestein, Joep and van Kempen, Zoé L E},
title = {Safety and patient experiences with the natalizumab biosimilar in multiple sclerosis treatment},
journal = {Multiple Sclerosis and Related Disorders},
year = {2026},
volume = {109},
pages = {107147},
doi = {10.1016/j.msard.2026.107147}
}
EUVIMED